{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:02:57Z","timestamp":1780963377289,"version":"3.54.1"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Autoimmune haemolytic anaemia (AIHA) and autoimmune thrombocytopenia are common complications of childhood-onset lupus, which may be life-threatening. A greater understanding of the pathogenesis of these haematologic manifestations will enhance our understanding of the biology of systemic lupus erythematosus (SLE) and inform the identification of novel treatments.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The mechanisms underlying AIHA and autoimmune thrombocytopenia are incompletely understood and likely multifactorial. Although the development of auto-antibodies is central to the disease process, recent studies have demonstrated the importance of cytokines in the underlying pathologic process. In-vitro and in-vivo evidence points to a role for IL17 in the pathogenesis of AIHA, which involves loss of tolerance to red cell auto-antigens and the development of autoantibodies. Sirolimus, an mTor inhibitor, has benefited patients with primary autoimmune cytopenias, possibly by stimulating T regulatory cells, and may also have efficacy for SLE-associated cytopenias. Similarly, low-dose recombinant human IL-2 therapy has shown promising results for improving platelet counts in patients with autoimmune thrombocytopenia, possibly by restoring the balance between T regulatory, T helper and Th17 cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The emergence of new agents directed at restoring immune dysregulation hold promise for the treatment of AIHA and autoimmune thrombocytopenia and should provide better tolerated alternatives to high-dose corticosteroids.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000523","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T16:23:14Z","timestamp":1530721394000},"page":"498-505","source":"Crossref","is-referenced-by-count":25,"title":["Autoimmune haemolytic anaemia and autoimmune thrombocytopenia in childhood-onset systemic lupus erythematosus: updates on pathogenesis and treatment"],"prefix":"10.1097","volume":"30","author":[{"given":"Jessica","family":"Neely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"von Scheven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pcl.2012.03.007","article-title":"Systemic lupus erythematosus in children and adolescents","volume":"59","author":"Levy","year":"2012","journal-title":"Pediatr Clin North Am"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0961203307088006","article-title":"Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children","volume":"17","author":"Ram\u00edrez G\u00f3mez","year":"2008","journal-title":"Lupus"},{"key":"R6-20230829","first-page":"1","article-title":"Distinct clinical correlates of immune thrombocytopenic purpura at diagnosis of childhood-onset and adult SLE","author":"Esteves","year":"2017","journal-title":"Mod Rheumatol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/0961203316676379","article-title":"Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients","volume":"26","author":"Gormezano","year":"2017","journal-title":"Lupus"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/pbc.25976","article-title":"Evans syndrome at childhood-onset systemic lupus erythematosus diagnosis: a large multicenter study","volume":"63","author":"Lube","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000439002","article-title":"New insights in the pathogenesis of autoimmune hemolytic anemia","volume":"42","author":"Barcellini","year":"2015","journal-title":"Transfus Med Hemother"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3324\/haematol.2009.013672","article-title":"Hypercoagulability and thrombotic complications in hemolytic anemias","volume":"94","author":"Ataga","year":"2009","journal-title":"Haematologica"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2752","article-title":"Taming lupus: a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Liu","year":"2012","journal-title":"Nat Med"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.molmed.2017.05.006","article-title":"Pathogenesis of human systemic lupus erythematosus: a cellular perspective","volume":"23","author":"Moulton","year":"2017","journal-title":"Trends Mol Med"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.exphem.2012.08.008","article-title":"Critical role of Th17 cells in development of autoimmune hemolytic anemia","volume":"40","author":"Xu","year":"2012","journal-title":"Exp Hematol"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2014.05.004","article-title":"Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus","volume":"154","author":"Martin","year":"2014","journal-title":"Clin Immunol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.24499","article-title":"Th17 and natural Treg cell population dynamics in systemic lupus erythematosus","volume":"60","author":"Yang","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R16-20230829","first-page":"297","article-title":"Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia","volume":"21","author":"Ahmad","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2010-05-283507","article-title":"Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study","volume":"116","author":"Comellas-Kirkerup","year":"2010","journal-title":"Blood"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5152\/eurjrheum.2015.0085","article-title":"The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus","volume":"3","author":"\u00dcnl\u00fc","year":"2016","journal-title":"Eur J Rheumatol"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/annrheumdis-2016-eular.5076","article-title":"ACTION on behalf of A. FRI0314\u2502Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS Action) clinical database and repository analysis: the impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients","volume":"75","author":"Zuily","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"e2818","DOI":"10.1097\/MD.0000000000002818","article-title":"Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients","volume":"95","author":"Jung","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"e5565","DOI":"10.1097\/MD.0000000000005565","article-title":"Clinical characteristics of immune thrombocytopenia associated with autoimmune disease: a retrospective study","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","article-title":"Pathobiology of secondary immune thrombocytopenia","volume":"46","author":"Cines","year":"2009","journal-title":"Semin Hematol"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"e86943","DOI":"10.1371\/journal.pone.0086943","article-title":"Detection of circulating B cells producing anti-GPIb autoantibodies in patients with immune thrombocytopenia","volume":"9","author":"Kuwana","year":"2014","journal-title":"PLoS One"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.1200452","article-title":"Megakaryocyte progenitors are the main APCs inducing Th17 response to lupus autoantigens and foreign antigens","volume":"188","author":"Kang","year":"2012","journal-title":"J Immunol"},{"key":"R30-20230829","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus","volume":"29","author":"Papo","year":"2002","journal-title":"J Rheumatol"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/03009740701607042","article-title":"Mycophenolate mofetil for nonrenal manifestations of systemic lupus erythematosus: a systematic review","volume":"36","author":"Mok","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1191\/0961203306lu2292oa","article-title":"Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases","volume":"15","author":"Gomard-Mennesson","year":"2006","journal-title":"Lupus"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-112-9-674","article-title":"Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus","volume":"112","author":"Boumpas","year":"1990","journal-title":"Ann Intern Med"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1542\/peds.2008-2361","article-title":"B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus","volume":"123","author":"Kumar","year":"2009","journal-title":"Pediatrics"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/0961203315578764","article-title":"Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus","volume":"24","author":"Olfat","year":"2015","journal-title":"Lupus"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias. A multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/0961203317711011","article-title":"Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study","volume":"27","author":"Li","year":"2018","journal-title":"Lupus"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3899\/jrheum.140080","article-title":"Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus","volume":"41","author":"Magnano","year":"2014","journal-title":"J Rheumatol"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/blood.V128.22.2542.2542","article-title":"Thrombopoietin-receptor agonist in systemic lupus erythematosus associated immune thrombocytopenia: results of the 16 patients from the French cohort","volume":"128","author":"Terriou","year":"2016","journal-title":"Blood"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0961203314559632","article-title":"Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus","volume":"24","author":"Maroun","year":"2015","journal-title":"Lupus"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(16)00279-8","article-title":"Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"Tarantino","year":"2016","journal-title":"Lancet"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1080\/14656566.2017.1373091","article-title":"Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review","volume":"18","author":"Zhang","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MPH.0000000000000818","article-title":"Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans syndrome (ES)","volume":"39","author":"Jasinski","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multiinstitutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mah\u00e9vas","year":"2015","journal-title":"J Autoimmun"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201809000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T06:37:36Z","timestamp":1693291056000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201809000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000523","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}